Dimitrios obtained a BSc in molecular biology from the Department of Biochemistry and Molecular Biology (now Structural and Molecular Biology), University College London, in 2001. His studies included an Industrial Placement year at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in Harlow, where he developed mass spectrometry-based methods for the study of protein post-translational modifications.
He then moved to Switzerland to pursue doctoral studies with Prof. Wilhelm Krek, first at the Friedrich Miescher Institute (FMI) in Basel, and then at the ETH-Zurich, where he investigated molecular mechanisms that underlie the regulation of sirtuins, a class of NAD-dependent deacetylases with roles in metabolic regulation and ageing. For this work, Dimitrios obtained his PhD in biochemistry from the University of Basel in 2006.
In 2007, Dimitrios joined the lab of Professor Lewis Cantley, at Beth Israel Deaconess Medical Center and the Department of Systems Biology, Harvard Medical School in Boston, USA, where he worked first as a Postdoctoral Fellow and, in 2012, as an Instructor in Medicine. His work focused on understanding metabolic reprogramming in cellular stress responses. He also contributed to the development of first-in-class small molecule activators that target the glycolytic enzyme pyruvate kinase M2 (PKM2) as potential therapeutics.
Dimitrios started his independent research group as a Programme Leader at the Medical Research Council (MRC) National Institute for Medical Research in October 2012 (now part of the Francis Crick Institute). He is also a recipient of an MRC Centenary Award (2012). His group uses biochemistry, proteomics, metabolomics, protein engineering and mouse models to understand metabolic regulation in health and disease, and to investigate the role of metabolic heterogeneity within the tumour microenvironment.